Effect of Different Treatments on the Prognosis of Early Cervical Cancer: A Multicenter, Prospective, Real-world Study
Effect of Different Treatments on the Prognosis of Early Cervical Cancer: A Multicenter, Prospective, Real-world Study
To observe the effects of different treatments on the oncological outcome and complications
 of early cervical cancer (2018 FIGO stage IA1 with lymphovascular space invasion and IA2-IIA2
 cervical cancer). This study prospectively collecting enrolled cervical cancer patients
 clinical data and outcome from June 2020 to June 2025. (Classification factors: preoperative
 neoadjuvant treatment , surgical approach, type of hysterectomy, whether to receive
 radiochemotherapy) . This study is an observational study, and segmented analysis according
 to different treatment methods.
Objectives: To observe the effects of different treatments on the oncological outcome and
 complications of early cervical cancer (2018 FIGO stage IA1 with lymphovascular space
 invasion and IA2-IIA2 cervical cancer).

 Study Design: We obtained the demographic, clinical, treatment hospital and complication data
 of patients with cervical cancer undergoing radical hysterectomy from 2004 to 2015 at 37
 hospitals. The patients were assigned into groups. Classification factors: preoperative
 neoadjuvant treatment (not received, neoadjuvant chemotherapy, preoperative radiotherapy) ,
 surgical approach (abdomincal, laparoscopic, vaginal, robotic surgery), type of hysterectomy
 (type B, type C1, type C2), primary treatment (radiochemotherapy or surgery).

 laparoscopic and abdominal surgery groups. The differences in the survival, complication
 rates, quality of life, and cost were analyzed using univariate and multivariable logistic
 regression models.
Inclusion Criteria:

 1. Histologically confirmed primary adenocarcinoma, squamous cell carcinoma,
 adenosquamous carcinoma, or other histological types carcinoma of the uterine cervix.

 2. Patients with Histologically confirmed stage IA1 (with lymph vascular invasion), FIGO
 2018 stage IA2 to IIA2.

 3. Underwent radical hysterectomy or radiochemotherapy.

 4. ECOG Performance Status of 0 or 1.

 Exclusion Criteria:

 1. Life expectancy is less than 6 months

 2. No prior malignancy

 3. ECOG Performance Status of 2 to 5.